Wilson disease is a treatable inherited disorder in which impaired ATP7B function prevents normal handling and biliary excretion of copper. Copper first accumulates in the liver and can later injure the brain, eyes, blood cells, kidneys, and other tissues. Genetic testing can confirm the diagnosis when two disease-causing ATP7B variants are identified, support testing of relatives, and resolve some difficult biochemical cases. It should not be used as the only diagnostic test. Ceruloplasmin, 24-hour urinary copper, slit-lamp examination, liver tests, neurologic assessment, and sometimes quantitative liver copper or newer exchangeable-copper measures provide complementary information. A person with Wilson disease may have a normal ceruloplasmin value, no Kayser–Fleischer rings, or only one detectable ATP7B variant. Conversely, low ceruloplasmin alone is not proof of disease. Because untreated Wilson disease can progress to irreversible neurologic injury, cirrhosis, or acute liver failure, clinicians integrate all available evidence and begin appropriate treatment without waiting for every uncertainty to disappear.
- Wilson disease is autosomal recessive and usually requires pathogenic variants in both ATP7B copies.
- Genetic testing complements biochemical and clinical evaluation; it does not replace it.
- Ceruloplasmin can be normal in affected people and low for reasons unrelated to Wilson disease.
- One pathogenic ATP7B variant may indicate carrier status or an incompletely solved diagnosis.
- Treatment is lifelong and may include a copper chelator, zinc, or liver transplantation in severe failure.
- Siblings and other at-risk relatives should be assessed promptly because presymptomatic treatment prevents injury.
Table of Contents
- How ATP7B controls copper
- One disease, many presentations
- Diagnosis is a mosaic of evidence
- What the genetic test examines
- Interpreting two, one, or no variants
- Treatment and response monitoring
- Family testing, pregnancy, and lifelong care
How ATP7B controls copper
Copper is an essential trace element used by enzymes involved in energy production, connective tissue, neurotransmitter synthesis, antioxidant defense, and iron metabolism. The body must absorb enough copper for these functions while preventing excess free copper from damaging proteins, membranes, and DNA. The liver is the central regulator.
ATP7B encodes a copper-transporting P-type ATPase expressed mainly in hepatocytes. At lower copper concentrations, ATP7B helps incorporate copper into apoceruloplasmin to form ceruloplasmin. When copper rises, ATP7B relocates within the cell and directs excess copper into bile, the main route of elimination. Pathogenic variants can impair protein folding, trafficking, ATPase activity, copper binding, or stability.
When both ATP7B copies have inadequate function, biliary copper excretion falls. Copper accumulates in hepatocytes, producing oxidative injury, inflammation, fibrosis, and cirrhosis. As storage capacity is exceeded, non-ceruloplasmin-bound copper enters the circulation and deposits in the brain, cornea, kidneys, joints, and other tissues. Sudden release from a severely injured liver can contribute to Coombs-negative hemolytic anemia and acute liver failure.
The disorder is monogenic, but its expression is highly variable. Two siblings with the same variants can present at different ages and with different organs affected. Variant type, residual protein activity, other genes, sex, diet, environment, and treatment timing may all contribute. A genotype cannot reliably predict whether a person will first develop hepatitis, tremor, psychiatric symptoms, or acute liver failure.
Wilson disease is not copper poisoning from a single exposure. It is a chronic failure of copper balance. Avoiding high-copper foods cannot restore biliary excretion, and dietary changes alone are not adequate treatment. Similarly, a serum copper value by itself can be confusing: total serum copper may be low because ceruloplasmin is low even while harmful tissue copper is excessive.
Treatment works because copper balance can be shifted. Chelators increase urinary copper removal, while zinc reduces intestinal absorption. Liver transplantation replaces the major organ responsible for defective ATP7B-mediated excretion and can correct the metabolic defect in acute or advanced hepatic failure. Early diagnosis offers the best chance to prevent permanent damage.
One disease, many presentations
Wilson disease can present from early childhood into later adulthood. Liver abnormalities are common in children and adolescents, but age alone should not exclude the diagnosis. Adults may first present with neurologic or psychiatric disease, and well-documented late-onset cases show that a cutoff such as age 40 is unsafe.
Hepatic presentations include asymptomatic elevation of aminotransferases, fatty-liver-like imaging, recurrent jaundice, acute hepatitis, autoimmune-hepatitis-like disease, portal hypertension, cirrhosis, or acute liver failure. The liver phenotype can resemble viral, metabolic, drug-induced, or autoimmune disease. Wilson disease should remain in the differential when the age and pattern fit, especially when the cause remains unexplained.
Neurologic findings include tremor, dystonia, slowness, rigidity, dysarthria, drooling, swallowing difficulty, impaired coordination, gait disturbance, and involuntary movements. Handwriting or school performance may deteriorate before a clear movement disorder is recognized. Brain magnetic resonance imaging may show abnormalities in the basal ganglia, brainstem, or other regions, but imaging is supportive rather than diagnostic by itself.
Psychiatric and behavioral changes can include depression, anxiety, irritability, impulsivity, personality change, psychosis, or declining executive function. A primary psychiatric diagnosis may coexist with Wilson disease, and common psychiatric symptoms alone do not justify ATP7B testing. Suspicion rises when psychiatric change accompanies neurologic signs, liver abnormalities, hemolysis, Kayser–Fleischer rings, or a family history.
Kayser–Fleischer rings are copper deposits in Descemet membrane at the corneal edge. A trained ophthalmologist uses slit-lamp examination to detect them. They are frequent in neurologic Wilson disease but may be absent in purely hepatic disease and in young children. Their presence supports the diagnosis in the correct context, but similar rings can rarely occur in other cholestatic disorders.
Other manifestations include Coombs-negative hemolytic anemia, kidney tubular dysfunction or stones, bone and joint disease, cardiomyopathy or rhythm abnormalities, menstrual irregularity, infertility, and muscle injury. No single feature is universal. The broad spectrum is why the diagnosis is assembled from several independent clues rather than one “Wilson blood test.”
Acute liver failure is an emergency. Wilson-related failure may feature jaundice, coagulopathy, encephalopathy, hemolysis, kidney injury, and a characteristic relationship between alkaline phosphatase and bilirubin, but no bedside pattern is perfectly specific. Urgent transplant-center assessment should proceed while diagnostic tests are obtained.
Diagnosis is a mosaic of evidence
Serum ceruloplasmin is commonly measured first. A very low value supports Wilson disease, but the test has important limitations. Ceruloplasmin is an acute-phase protein and can rise with inflammation, pregnancy, or estrogen exposure. It may be low in severe liver failure, protein loss, malnutrition, Menkes disease, aceruloplasminemia, and some healthy carriers. Immunologic assays may count both copper-loaded and copper-free protein, making results method dependent.
Twenty-four-hour urinary copper estimates copper excretion without a chelator. Elevated excretion supports the diagnosis, particularly in symptomatic disease. Collection errors, kidney impairment, cholestatic liver disease, acute hepatitis, and contamination can affect results. The laboratory should provide appropriate copper-free collection instructions, and an unexpectedly low or high value may need repetition.
Total serum copper is usually reduced when ceruloplasmin is low, but non-ceruloplasmin-bound copper may be increased. Calculated “free copper” can be unreliable because small measurement errors are magnified. Directly measured exchangeable copper and relative exchangeable copper are promising and are incorporated into some contemporary diagnostic pathways where validated testing is available.
A slit-lamp examination, liver biochemistry, complete blood count, coagulation tests, hemolysis studies, neurologic examination, and brain MRI contribute according to the presentation. Quantitative hepatic copper measured in an adequate liver-biopsy specimen can support the diagnosis, but copper distribution may be patchy, and cholestatic disorders can also elevate hepatic copper. Biopsy additionally assesses inflammation, fibrosis, or another liver diagnosis, but it is not required in every patient.
The Leipzig scoring system combines Kayser–Fleischer rings, neurologic findings, ceruloplasmin, hemolysis, urinary copper, hepatic copper, and ATP7B results. It standardizes evidence rather than replacing clinical judgment. Different age groups and acute liver failure require nuanced interpretation, and newer guidelines refine how individual components are used.
No single normal result excludes Wilson disease. A patient with convincing hepatic disease may lack rings; a neurologic patient may have near-normal liver enzymes; an affected person may have ceruloplasmin above a traditional threshold. Conversely, one abnormal measure should not bypass differential diagnosis. The strength comes from concordance among independent findings.
Treatment should not be dangerously delayed in a highly likely symptomatic case while waiting for prolonged genetic analysis. The clinical team can begin appropriate therapy and continue resolving the molecular diagnosis, especially when hepatic failure or progressive neurologic disease is present.
What the genetic test examines
Clinical testing sequences ATP7B coding exons and splice junctions to identify single-nucleotide variants and small insertions or deletions. A complete assay should also state whether exon-level deletions and duplications are assessed. Although copy-number changes are less common than sequence variants, they can explain cases in which one pathogenic variant is found by sequencing.
ATP7B has a large and diverse variant spectrum. Certain variants are more frequent in particular populations—p.His1069Gln in parts of Europe and p.Arg778Leu in several East Asian populations, for example—but ancestry-specific common variants do not justify testing only one position in a person with suspected disease. Compound heterozygosity, with a different pathogenic variant on each chromosome, is common.
Targeted testing is appropriate when the exact familial variants are known. For a new diagnostic case, full sequencing plus deletion-duplication analysis is more reliable than a limited founder panel unless a validated population strategy is being used. Laboratories should use current transcripts and standardized Human Genome Variation Society notation so that family reports can be compared.
Broader liver-disease, movement-disorder, or metabolic panels may be useful when the phenotype is unclear. These can identify another cause but also generate incidental and uncertain findings. Exome or genome sequencing may detect ATP7B variants missed by older testing, yet short-read methods can still miss deep intronic changes, complex rearrangements, or some regulatory variants.
Phase matters. Wilson disease usually requires two pathogenic or likely pathogenic variants in trans—one inherited from each parent. When two variants are found but parental samples are unavailable, the laboratory may use read data, allele-specific methods, or family studies to determine whether they are on opposite chromosomes. Two variants in cis, on the same chromosome, may represent carrier status rather than biallelic disease.
Pretest counseling should explain the possibility of two, one, or no pathogenic variants; a variant of uncertain significance; incidental findings from a broad panel; and implications for relatives. Genetic testing can also be performed rapidly in selected urgent settings, but availability and turnaround vary. Acute management remains guided by clinical severity.
Interpreting two, one, or no variants
Two pathogenic or likely pathogenic ATP7B variants in trans provide strong molecular confirmation of Wilson disease. The genotype should still be reconciled with the person’s findings because labeling errors, phase uncertainty, or an unrelated coexisting disorder can occur. A confirmed result enables precise testing of siblings and other relatives and may spare them from repeated ambiguous biochemical screening.
Two variants do not predict exact severity. A person with variants often associated with residual function may still develop important disease, and a genotype reported in a severe case does not guarantee the same course in a sibling. Treatment decisions depend on symptoms, liver status, neurologic findings, copper measures, and response—not on a simple “mild” or “severe” variant label.
One pathogenic ATP7B variant has several possible meanings. The person may be an unaffected carrier whose symptoms have another cause. A second disease-causing variant may have been missed because it is deep intronic, structural, regulatory, or technically difficult. The reported variant may be in trans with a VUS that later proves pathogenic. Biochemical and clinical evidence determines whether the case remains strongly suspected and whether expanded testing is warranted.
A VUS is not diagnostic and should not be counted as a pathogenic allele merely to complete a recessive genotype. Population frequency, computational predictions, conservation, functional studies, segregation, RNA data, and independent affected cases may help reclassification. Treatment of an ill patient can be justified by the clinical diagnosis while the VUS remains unresolved, but predictive testing of healthy relatives should not be based on uncertainty.
A negative genetic test does not absolutely exclude Wilson disease. Older assays may have omitted deletion-duplication analysis, and current clinical methods do not capture every possible ATP7B defect. The clinician should review assay scope, confirm that the phenotype and biochemical data were interpreted correctly, and consider reanalysis, RNA studies, genome sequencing, or alternative diagnoses.
A single heterozygous variant in an asymptomatic relative usually indicates carrier status. Carriers do not generally develop Wilson disease because one functional ATP7B copy is sufficient, although some may have mildly altered copper measures. Carrier status should not lead to chelation. The key exception is when symptoms and biochemical evidence suggest that a second variant remains unidentified.
Reports may be reclassified as databases and functional evidence improve. Families should keep exact copies of all variant nomenclature and know how the laboratory communicates updates. A common name such as “H1069Q” is not enough for reliable cascade testing without the complete clinical report.
Treatment and response monitoring
Symptomatic Wilson disease is treated by removing accumulated copper and preventing reaccumulation. D-penicillamine and trientine are chelators that bind copper and increase urinary excretion. Choice depends on hepatic versus neurologic presentation, availability, prior response, adverse effects, pregnancy, kidney function, and clinician experience. Some patients with neurologic disease worsen after treatment begins, especially when copper is mobilized too rapidly, so dose escalation and monitoring require expertise.
Zinc salts induce intestinal metallothionein, which binds copper and reduces absorption. Zinc can be used for selected presymptomatic patients, maintenance therapy, or other situations according to guideline and center practice. It must be timed away from food and chelators to avoid interference. Gastrointestinal intolerance and adherence problems are common enough to require active follow-up.
Treatment is lifelong unless liver transplantation has corrected the metabolic defect. Stopping medication because symptoms improve allows copper to reaccumulate and can lead to sudden hepatic or neurologic deterioration. A low-copper diet may reduce exposure during initial treatment—particularly avoidance of very copper-rich foods and unregulated supplements—but it is an adjunct, not a substitute for medication.
Monitoring asks whether therapy is effective, taken correctly, and not excessive. Clinicians track liver tests, blood counts, urinalysis, kidney function, symptoms, neurologic examination, and copper indices. Twenty-four-hour urinary copper has different expected patterns with chelators and zinc. Values that are too high may indicate inadequate control or nonadherence; values that are very low with cytopenias or neurologic symptoms may suggest copper deficiency or overtreatment.
D-penicillamine can cause hypersensitivity, kidney injury, bone-marrow suppression, autoimmune complications, and other adverse effects. Trientine can also cause iron deficiency, gastrointestinal effects, or overtreatment, though its profile differs. Zinc may cause gastric irritation and biochemical abnormalities. Patients need a specific laboratory schedule rather than assuming that “natural” zinc is harmless.
Acute liver failure, decompensated cirrhosis unresponsive to medical therapy, or a poor prognostic score can require urgent transplantation. Transplant assessment should not be delayed by a pending genetic result. For neurologic Wilson disease without severe liver failure, transplantation is not routine and requires highly specialized consideration.
Neurologic and psychiatric recovery can lag behind copper control and may be incomplete after longstanding injury. Physical, occupational, speech, swallowing, nutritional, and psychiatric care are often necessary alongside anti-copper therapy. Improvement should be judged over appropriate intervals rather than by one laboratory value.
Family testing, pregnancy, and lifelong care
Wilson disease follows autosomal recessive inheritance. When both parents are carriers, each pregnancy has a 25% chance of an affected child, a 50% chance of a carrier, and a 25% chance of a child who inherited neither familial variant. These probabilities reset for every pregnancy.
Siblings of an affected person have the highest immediate priority for evaluation because they may already be accumulating copper without symptoms. When both familial variants are known, targeted genetic testing provides a clear answer. Biochemical evaluation may be performed in parallel, particularly when treatment must begin promptly or molecular phase is not fully resolved. Parents are usually carriers, but parental testing confirms phase and can detect unexpected de novo or mosaic findings.
Children of a person with Wilson disease inherit at least one pathogenic variant and are obligate carriers unless the affected parent has an unusual molecular configuration. They are affected only if the other parent also contributes a pathogenic ATP7B variant. Partner carrier testing may be considered, especially with consanguinity, shared ancestry with a higher carrier frequency, or reproductive planning. Testing strategy should use comprehensive analysis rather than a narrow founder variant when appropriate.
Presymptomatic affected relatives require treatment even when liver tests are normal. The goal is prevention, not waiting for copper injury to become visible. Carriers do not need treatment but should retain the report for their own reproductive counseling.
Pregnancy is possible for many people with treated Wilson disease. Anti-copper therapy is generally continued because stopping can cause dangerous hepatic decompensation or neurologic worsening. Dose adjustments may be needed, particularly near delivery, and chelator exposure, wound healing, maternal copper control, and fetal considerations should be reviewed by hepatology and maternal-fetal medicine. Zinc and chelators have different evidence and monitoring needs; medication should never be stopped without the treating team.
Prenatal diagnosis and preimplantation genetic testing are possible when the familial pathogenic variants are established. These are personal choices. Testing can determine whether the fetus inherited the variants but cannot predict the exact organ presentation or age of onset. Counseling should clearly distinguish an affected biallelic genotype from carrier status.
Long-term care is multidisciplinary. Hepatology, neurology, psychiatry, genetics, ophthalmology, nutrition, and primary care may all contribute. Patients should carry an updated medication list, avoid copper-containing supplements unless prescribed, and tell clinicians that uninterrupted Wilson therapy is essential during hospitalization. With early diagnosis, sustained treatment, and careful monitoring, many people can prevent progression and maintain good long-term health.
References
- EASL-ERN Clinical Practice Guidelines on Wilson’s disease. European clinical practice guideline, 2025.
- A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance from the American Association for the Study of Liver Diseases. Clinical practice guidance, 2022.
- Wilson disease: a summary of the updated AASLD Practice Guidance. Guideline summary and clinical review, 2023.
- Wilson Disease. GeneReviews clinical reference, updated 2023.
- Wilson’s Disease—Genetic Puzzles with Diagnostic Implications. Genetics and diagnostic review, 2023.
- Clinical and genetic characterization of patients with late-onset Wilson’s disease. Clinical genetics study, 2024.
Disclaimer
This article is for general education and does not diagnose Wilson disease or provide an individualized treatment plan. ATP7B results must be interpreted with copper studies, liver and neurologic findings, family data, and the complete laboratory report by qualified specialists. Jaundice with confusion, bleeding, severe weakness, sudden neurologic decline, or suspected acute liver failure requires urgent medical care.
